Counters to Clever Stupidity

A Second Steering on intellectual property

The original Clever Stupidity Third Thought established the mechanism. Intellectual property law manufactures scarcity where none physically exists, captures the language of creator protection while delivering the proceeds to whoever holds the rights, and produces locally rational behaviour that is systemically destructive. Clever stupidity.

A good framework should survive pressure. This one got three challenges — and the pressure improved it. What follows is the record of that process.

The first challenge came from a professional creative reader who identified a hole in the original argument. The second came from the argument itself, when Rob and an AI interlocutor argued about the reader's counter and found that the counter had a counter, which had a counter, which eventually landed somewhere none of the original positions had anticipated. The third came from the evidence, when the evolved argument was tested against a case study and the case study broke the framework in a different place than expected.

This is what Paragentism's Steering 2 looks like in practice: not defending the original position, but following the logic wherever it goes. The AI didn't validate the argument. It pushed back on it, got pushed back on in return, and the friction produced something better than either starting position. That is the correct use of a tool that most people use to feel clever rather than become so.

The reproduction cost problem

The toll bridge section in the first Third Thought argued that ideas fail the two tests for property — rivalrous and excludable — and that IP law manufactures those qualities by decree. A sharp reader, who is a professional creative, identified what that argument skips past.

Creation is expensive. Copying is almost free for some forms of IP and substantially cheaper for others. A novelist spends two years writing a book that can be pirated in seconds. A pharmaceutical company spends a billion dollars developing a drug that a generic manufacturer can reproduce for cents per pill. The low marginal cost of reproduction is the one economic problem IP law is trying to solve. The other is how to compensate creators appropriately later, when at the time of creating the IP its value is zero, low, or unknown.

Conceded. Both problems are real and the original argument was cleaner than it deserved to be.

But here is what the concession opens up. Low marginal reproduction cost is precisely why the bundling fails. You need protection long enough for a creator to recover fixed costs — the two years, the billion dollars — plus a risk premium for the value that couldn't be known at the time of creation. After that point the monopoly serves no incentive function. It is pure rent. The questions IP law has never honestly asked itself are: how much protection is enough to recover the investment? How much is extraction on top? And how does the risk of future value — the possibility that a work becomes worth far more than anyone anticipated — change those current valuations?

The first Third Thought proposed unbundling as the direction: creation, distribution, and derivative use as three distinct economic layers each requiring different treatment, analogous to the forced separation of railway track, train operation, and retail scheduling. The reproduction cost argument gives that proposal its economic rationale. Creation is expensive and future value is unknown — that layer needs protection calibrated to recovery plus risk. Distribution is where low marginal reproduction cost actually lives — that layer needs time-limited regulated access, not a seventy-year monopoly. Derivative use and building-on should expire into the commons because the commons funds the next generation of creation.

The honest caveat is that unbundling points toward a solution without constituting one. The questions of how to calibrate each layer, how to handle unknown future value at the creation stage, and how to prevent the distribution layer from being captured the same way the current system was — those remain open. The railway analogy shows the shape of the answer. It doesn't fill it in. Statute of Anne's fourteen years was a rough attempt at the calibration. Life plus seventy years is the calibration abandoned entirely in favour of extraction. The distance between those two positions is where the work still needs to be done.

The Monroe problem

Marilyn Monroe was paid fifty dollars in 1949 for a photograph that generated an empire. She received nothing from its success, and said so explicitly: I never even received a thank-you from all those who made millions off a nude Marilyn photograph. I even had to buy a copy of the magazine to see myself in it. The instinctive response is that something was wrong — that she was exploited, that the transaction was unconscionable, that IP law failed her.

The first counter: compare Halle Berry, who was paid five hundred thousand dollars to appear topless in Swordfish. Monroe got fifty dollars. Famous breasts are more valuable than unknown breasts. The fame seems far more important than aesthetic beauty. Berry proves the market prices differently — perhaps more correctly — for known fame at the time of exchange.

The counter to that counter: Berry had market knowledge. Monroe didn't. The asymmetry of information, not just price, is what makes the original transaction suspect. Employment law already has a mechanism for this — unconscionable contracts are unenforceable when the imbalance was knowable to one party.

But that counter doesn't survive either. Neither Monroe nor the photographer had future market knowledge. Nobody in that room in 1949 knew what Marilyn Monroe would become. Fifty dollars for an unknown was probably the correct market price for an unknown. Berry proves the market prices differently — perhaps more correctly — for known fame, which means Monroe's transaction wasn't exploitative at the time. It was unlucky for Monroe, a bit better for the 1949 photographer who sold the rights for nine hundred dollars, and a windfall for Hefner who leveraged it better than the other two players combined.

The Playboy appearance did boost Monroe's career. She acknowledged it hadn't hurt her. The fame dividend was real, even if she resented receiving none of the financial upside. Which makes the unconscionable contract argument collapse further — she got something, just not money.

What remains is more interesting than exploitation. The injustice in Monroe's situation is not that she was cheated. It is that IP law created enormous long-term value in rights ownership and then had nothing to say to the person whose face and body generated that value, because she had already signed a piece of paper that was fair at the time. A fair transaction produced an unfair outcome when value compounded beyond what either party could foresee. That is not a contract problem. You cannot fix it with better drafting or sharper lawyers.

Which brings us to a thought experiment. You are paid to give blood. Researchers find a cure for something in your blood. You receive nothing further. The transaction was fair. The use changed. The value compounded beyond anything either party anticipated. IP law has no mechanism for this — and neither does contract law, property law, or any other framework currently on offer. This is the change-of-use problem, the same structural gap that occurs when developers extract value from changing the use of land, and it is a hole the original argument didn't identify.

That is a sharper critique than exploitation. Exploitation implies a bad actor. This doesn't require one.

The Merck problem

Brazil's compulsion of Merck's efavirenz patent in 2001 produced three distinct responses, each one better than the last.

The first: Merck was wrong. The patent created artificial scarcity during a public health emergency. People were dying. The state was right to override it.

The second: Merck was also commercially stupid. Brazilian HIV patients, maintained on affordable antiretrovirals, were future customers in a growing market. Pricing them out of treatment violated Steering 1 — are creators being incentivised to create, or are they destroying the market that justifies the incentive? You do not build a sustainable pharmaceutical business by killing the people in it.

The third, and the one that settles it: it was asserted that Brazilian patients were not addressable at any margin-positive price. This is not true. Merck's development costs for efavirenz were already recovered. They could have supplied Brazil at cost plus a modest margin, made real money, retained customers in a growing middle-income market, neutralised the legal threat, and banked the reputational dividend of being the pharmaceutical company that chose people over precedent. The Doha Declaration neutralised the precedent regardless. Merck lost the precedent, the reputation, the margin, and the customers simultaneously.

This is not clever stupidity. Clever stupidity requires local rationality. There is no reading of Merck's position in which their decision was locally rational. They optimised for a precedent that evaporated, at the cost of everything else.

The technical term, deployed with precision, is Fuckwittery. Merck were Fuckwits. Greedy, short-sighted, stupid, and immoral Fuckwits — which is a distinct and worse category than clever stupidity, and worth naming separately.

What the pressure produced

The original argument was: IP law is a category error, manufacturing scarcity where none exists, serving extraction rather than creation.

The pressure produced three refinements. First: the category error understates the real problem — creation costs are real, reproduction costs are low, and the future value of IP at the time of creation is often unknown. The critique is not that protection is wrong. It is that the protection granted is wildly disproportionate to the protection required, and the questions needed to calibrate it correctly have never been seriously asked. Second: exploitation is the wrong frame for understanding who IP law fails — the Monroe problem is not bad actors but structural absence, a system with no mechanism for fairness when value compounds beyond anticipation or when use changes beyond what either party imagined. Third: clever stupidity has a ceiling — when local rationality also breaks down, you are looking at something worse. Fuckwittery. The Merck case is the proof.

The framework holds. It just holds more precisely than it did before.